Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,517 | 1 | 46.4% |
| Travel and Lodging | $1,014 | 3 | 31.0% |
| Food and Beverage | $739.86 | 6 | 22.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $2,914 | 6 | $0 (2022) |
| Paragonix Technologies, Inc. | $201.34 | 1 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $120.89 | 1 | $0 (2024) |
| Horizon Therapeutics plc | $18.25 | 1 | $0 (2023) |
| Veloxis Pharmaceuticals, Inc. | $16.08 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $322.23 | 2 | Paragonix Technologies, Inc. ($201.34) |
| 2023 | $34.33 | 2 | Horizon Therapeutics plc ($18.25) |
| 2022 | $1,517 | 1 | CSL Behring ($1,517) |
| 2017 | $1,397 | 5 | CSL Behring ($1,397) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/07/2024 | SANOFI-AVENTIS U.S. LLC | THYMOGLOBULIN (Biological) | Food and Beverage | In-kind items and services | $120.89 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Paragonix Technologies, Inc. | SherpaPak (Device), LiverGuard, LungGuard | Food and Beverage | In-kind items and services | $201.34 | General |
| Category: Cardiology | ||||||
| 11/02/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: KRYSTEXXA | ||||||
| 01/31/2023 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: TRANSPLANTATION | ||||||
| 07/20/2022 | CSL Behring | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,516.88 | General |
| 10/11/2017 | CSL Behring | Product in Development (Biological) | Travel and Lodging | In-kind items and services | $437.40 | General |
| Category: Product in Development | ||||||
| 10/11/2017 | CSL Behring | Product in Development (Biological) | Travel and Lodging | In-kind items and services | $351.03 | General |
| Category: Product in Development | ||||||
| 10/11/2017 | CSL Behring | Product in Development (Biological) | Travel and Lodging | In-kind items and services | $225.39 | General |
| Category: Product in Development | ||||||
| 10/11/2017 | CSL Behring | Product in Development (Biological) | Food and Beverage | In-kind items and services | $191.65 | General |
| Category: Product in Development | ||||||
| 10/11/2017 | CSL Behring | Product in Development (Biological) | Food and Beverage | In-kind items and services | $191.65 | General |
| Category: Product in Development | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 439 | 728 | $367,182 | $69,662 |
| 2022 | 9 | 521 | 886 | $326,250 | $69,054 |
| 2021 | 10 | 606 | 1,137 | $374,036 | $92,285 |
| 2020 | 15 | 794 | 1,648 | $481,879 | $102,695 |
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 105 | 303 | $126,754 | $30,237 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 88 | 118 | $68,896 | $13,372 | 19.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 64 | 70 | $70,076 | $10,139 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 65 | 66 | $21,694 | $4,093 | 18.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 64 | $19,126 | $3,808 | 19.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 29 | $21,432 | $2,904 | 13.5% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 13 | 32 | $19,934 | $2,312 | 11.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 22 | 28 | $13,546 | $1,639 | 12.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 18 | $5,724 | $1,158 | 20.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 87 | 220 | $63,600 | $16,682 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 142 | 221 | $70,278 | $15,037 | 21.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 83 | 160 | $68,640 | $14,885 | 21.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 48 | $24,140 | $7,063 | 29.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 58 | 107 | $20,897 | $5,351 | 25.6% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2022 | 22 | 25 | $20,975 | $3,304 | 15.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 35 | 37 | $6,763 | $1,952 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 23 | $7,314 | $1,646 | 22.5% |
| 50200 | Needle biopsy of kidney | Facility | 2022 | 17 | 17 | $32,555 | $1,634 | 5.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 17 | 28 | $11,088 | $1,501 | 13.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 181 | 372 | $159,588 | $36,454 | 22.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 111 | 307 | $84,732 | $23,301 | 27.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 86 | 182 | $30,758 | $9,692 | 31.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 91 | 118 | $37,524 | $7,637 | 20.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 42 | 42 | $19,824 | $6,003 | 30.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $11,742 | $2,958 | 25.2% |
About Dr. Beatrice Concepcion, M.D
Dr. Beatrice Concepcion, M.D is a Nephrology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/19/2008. The National Provider Identifier (NPI) number assigned to this provider is 1518143551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Beatrice Concepcion, M.D has received a total of $3,271 in payments from pharmaceutical and medical device companies, with $322.23 received in 2024. These payments were reported across 10 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1,517).
As a Medicare-enrolled provider, Concepcion has provided services to 2,360 Medicare beneficiaries, totaling 4,399 services with total Medicare billing of $333,696. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Chicago, IL
- Active Since 01/19/2008
- Last Updated 04/05/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1518143551
Products in Payments
- Product in Development (Biological) $1,397
- SherpaPak (Device) $201.34
- THYMOGLOBULIN (Biological) $120.89
- KRYSTEXXA (Biological) $18.25
- ENVARSUS (Drug) $16.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Chicago
Nicole Stankus
Nephrology — Payments: $241,812
Susan Quaggin, Md, MD
Nephrology — Payments: $235,919
Lorenzo Gallon, Md, MD
Nephrology — Payments: $187,956
John Friedewald, Md, MD
Nephrology — Payments: $131,619
Arlene Chapman
Nephrology — Payments: $125,467
Dr. Jay Koyner, M.d, M.D
Nephrology — Payments: $87,521